Comparative Effectiveness of 5 Smoking Cessation Pharmacotherapies in Primary Care Clinics

Authors:
  • DMDanielle E. McCarthy
    Danielle E. McCarthy
  • SJSandra J. Japuntich
    Sandra J. Japuntich
  • BCBruce Christiansen
    Bruce Christiansen
  • MPMegan E. Piper
    Megan E. Piper
  • DJDouglas E. Jorenby
    Douglas E. Jorenby
  • DFDavid L. Fraser
    David L. Fraser
  • MFMichael C. Fiore
    Michael C. Fiore
  • TBTimothy B. Baker
    Timothy B. Baker
  • TJThomas C. Jackson
    Thomas C. Jackson

Abstract
Tobacco use continues to be a significant health threat, with approximately 438 000 smoking-related deaths occurring annually in the United States.1 However, substantial progress has been made in the last 40 years in reducing smoking prevalence from 42.4% in 1965 to 20% in 2007.2,3 In part, these declines are the result of the development of effective cessation treatments. For example, meta-analyses of 86 cessation medication studies in the US Public Health Service (PHS) clinical practice guideline Treating Tobacco Use and Dependence: 2008 Update4 (hereafter, 2008 PHS Guideline) confirmed the efficacy of all 7 Food and Drug Administration (FDA)-approved medications as well as nortriptyline hydrochloride, clonidine, and various combination therapies (eg, bupropion hydrochloride sustained release [SR] + nicotine patch). Yet, most data on cessation pharmacotherapies come from placebo-controlled efficacy trials conducted under ideal circumstance (eg, with motivated volunteers, inducements for participation, extensive participant contact), with few directly contrasting multiple pharmacotherapies in head-to-head comparisons. Even fewer studies have conducted such head-to-head tests in real-world clinic settings.4

This publication has 28 references indexed in Scilit: